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ABSTRACT
A carefully controlled study allowed us to compare the sensitivity of ASL (arterial
spin labeling) and BOLD (blood oxygen level dependent) fMRI for detecting the
effects of the adenosine A2a antagonist tozadenant in Parkinson disease. The study
compared the effect of drug directly or the interaction of the drug with a cognitive
task. Only ASL detected the direct effect of tozadenant. BOLD was more sensitive to
the cognitive task, which (unlike most drugs) allows on–off comparisons over short
periods of time. Neither ASL nor BOLD could detect a cognitive-pharmacological
interaction. These results are consistent with the known relative advantages of each
fMRI method, and suggest that for drug development, directly imaging pharma-
codynamic effects with ASL may have advantages over cognitive-pharmacological
interaction BOLD, which has hitherto been the more common approach to pharma-
cological fMRI.
Subjects Neuroscience, Neurology, Radiology and Medical Imaging
Keywords phMRI (pharmacological fMRI), Functional magnetic resonance imaging, Pulsed
arterial spin labeling, Tozadenant, Statistical parametric mapping, Arterial spin labeling (ASL),
BOLD, Parkinson disease
INTRODUCTION
Pharmacological magnetic resonance imaging (phMRI) uses fMRI to determine
drug-induced changes in brain activity and has multiple applications for pharmaceutical
development and efficacy testing. Before the development of functional MRI (fMRI),
pharmacological brain imaging most often directly compared brain activity on drug to
brain activity off drug (Herscovitch, 2001; McCulloch, 1982). Generally, phMRI studies
have avoided this direct approach. Some used drugs with rapid onset and rapid decay of
action, and correlated brain BOLD (blood oxygen level dependent) signal with noticeable
transient physiological effects, e.g., repeated ratings of cocaine-induced “high” (Breiter
et al., 1997). Other phMRI studies used drugs with rapid uptake and rapid elimination,
with sequential measurements of plasma concentration, to detect brain changes with the
How to cite this article Stewart et al. (2014), Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmaco-
logical fMRI. PeerJ 2:e687; DOI 10.7717/peerj.687
expected pharmacokinetics (Bloom et al., 1999). Drug effects on functional connectivity
have also been examined (Schwarz et al., 2007). The most common phMRI approach
examines the interactive effects of a drug on the BOLD signal changes induced by a
cognitive or sensory stimulus (Cole, Schwarz & Schmidt, 2012; Moeller et al., 2012; Wise et
al., 2002). All of these study designs were motivated in part by limitations of BOLD fMRI,
whose signal is nonquantitative and fluctuates artifactually over space and time (Iannetti &
Wise, 2007).
By contrast, ASL (arterial spin labeling) is an fMRI method that produces a temporally
stable signal. Additionally, ASL images reflect regional cerebral blood flow (rCBF) and
thus allow relatively straightforward physiological interpretation. These advantages have
led some recent drug discovery phMRI studies to use ASL (for reviews, see: Wang et al.,
2011; Zelaya et al., in press). Citalopram (Chen et al., 2011) and amphetamine (Nordin et
al., 2013) are two examples of psychoactive drugs studied using ASL.
These considerations, and our experience with pharmacological challenge positron
emission tomography (PET) blood flow imaging (e.g., Black et al., 2002; Hershey et al.,
1998), led us to choose a pure pharmacological challenge approach with perfusion fMRI
for a pharmacological challenge MRI study in Parkinson disease (Black et al., 2010b).
However, we designed the study so that we would also have data from the more prevalent
BOLD drug-task interaction design. The resulting data set allows a fair comparison of
these two methods, i.e., subjects provided imaging data for both methods during the same
imaging sessions, with similar drug concentrations, the same task, and similar total MRI
acquisition times. While previous studies have used ASL for phMRI, to our knowledge this
is the first direct comparison of ASL and BOLD for phMRI.
MATERIALS & METHODS
Study participants
Fourteen nondemented, nondepressed, ambulatory adults age 40–75, 11 men, with
idiopathic Parkinson disease, Hoehn & Yahr stage 1–3 (mean stage 2) (Hoehn & Yahr,
1967), treated with a stable dose of levodopa but no dopamine agonists, participated in the
clinical trial (registered at http://clinicaltrials.gov with identifier NCT00605553). Detailed
inclusion and exclusion criteria were reported previously (Black et al., 2010a). The study
was approved by the Washington University Human Research Protection Office (IRB),
approval # 08-0059, and all subjects provided written documentation of informed consent
prior to participation.
Study protocol
Subjects were randomly assigned to one of two treatment groups: one group took 60 mg
of the adenosine A2a antagonist tozadenant (SYN115) twice daily for one week, waited
for a one week washout period and then took a matching placebo twice daily for one
week; those assigned to the other group participated in the reverse order. The original
report included additional subjects allocated to 20 mg vs placebo, but for this report
we focus only on the 60 mg arms. Adenosine A2a antagonists have been studied eagerly
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Figure 1 Scan day study design. Each BOLD run comprised 10 s fixation, 50 s 2-back, 30 s fixation, 50 s
2-back, 30 s fixation, 50 s 2-back, and 40 s fixation.
as potential treatments for Parkinson disease, alone or in combination with standard
antiparkinsonian therapy (Pinna, 2014). A2a receptors occur together with dopamine D2
and D3 receptors on striatopallidal neurons that inhibit the indirect basal ganglia pathway,
and A2a antagonists mimic some of the biological effects of dopamine D2 and D3 agonists
(reviewed in Black et al., 2010b).
Subjects and investigators were blind to the group assignments. Neuroimaging was
performed on the last day of each treatment week. On the morning of the scan day, they did
not take their usual antiparkinsonian medications, but did take the last dose of tozadenant
or placebo at approximately 6:00 AM. The timing of the fMRI assessments was planned
to approximately bracket the time to maximal plasma concentration of tozadenant after
chronic dosing. Subjects took 200 mg of carbidopa on arrival to the imaging center and
then underwent two sets of MRI assessments, once before and once during an infusion
of levodopa, dosed to produce a steady plasma concentration of 600 ng/mL. Levodopa is
a precursor to dopamine and is used in Parkinson’s disease to ameliorate the deficiency
of dopamine in the substantia nigra. The carbidopa pretreatment was given to inhibit
peripheral metabolism of the upcoming levodopa infusion, minimizing side effects from
dopamine production in the periphery and keeping more of the levodopa available to the
brain.
Subject behavior
Each scanning session included two perfusion MRI (ASL) runs while the subject
performed the 2-back memory task, two control ASL runs while the subject fixated on
a crosshair, and two block-design BOLD runs, each with four fixation blocks bracketing
three task blocks (Fig. 1). ASL scans were also obtained for additional tasks without a
BOLD comparison. In each session the fixation ASL and 2-back ASL scans were acquired
immediately after the BOLD runs. The 2-back task inter-stimulus interval was 2.5 s for
both ASL and BOLD.
This study employed a working memory task for several reasons. Working memory
performance is affected by Parkinson disease and is sensitive to manipulations of central
dopaminergic transmission (Cools & D’Esposito, 2011; Hershey et al., 2004). Adenosine A2a
receptor antagonists interact with dopamine receptors and can improve working memory
performance (Takahashi, Pamplona & Prediger, 2008), including in animal models of
parkinsonism (Kadowaki Horita et al., 2013). Several cognitive-pharmacological interac-
tion phMRI studies have employed working memory tasks (Barch et al., 2012), including
another study with tozadenant (Moeller et al., 2012). For these and other reasons, several
A2a antagonists have been studied for possible cognitive benefits in PD (Pinna, 2014).
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One subject was excluded from all analyses presented here because his 2-back task
performance was less than 70% accurate. All other subjects had greater than 70% on
every run. We previously reported that tozadenant at this dose had no statistically
significant effect on 2-back performance, including accuracy and response time (Campbell
et al., 2010).
MR image acquisition
All MRI data were acquired at 3T on the Siemens Magnetron Tim Trio with the 12-channel
matrix head coil. BOLD-sensitive echo-planar images (EPI) were obtained with flip angle
90◦, echo time (TE) 27 ms, repetition time (TR) 2000 ms, 36 planes with interleaved slice
acquisition, field of view (256 mm)2, and voxel size (4.0 mm)3. Over a period of 4.33 min
for each run, 130 volumes (frames) were acquired; the first 4 frames were discarded to
ensure steady-state magnetization.
ASL images were acquired with the commercial Siemens pulsed ASL (pASL) sequence
(Wang et al., 2003b). Fifteen transverse echo-planar readout slices with center-to-center
slice distance 7.5 mm were acquired with (64)2 (3.4375 mm)2 voxels in each plane, TE 13.0
ms, TR 2600 ms, and flip angle 90◦. Labeling slab thickness was 10 cm. Fat suppression
was used. The perfusion mode was PICORE Q2T, with TI1 700 ms, saturation stop time
1600 ms and TI2 1800 ms. An M0 image was followed by 31 tag–control pairs for a total
acquisition time for each ASL run of 2.73 min.
Brain structure was assessed from sagittal magnetization-prepared rapid gradient-echo
(MP RAGE) acquisitions with voxel size (1.0 mm)3, TE= 3.08 ms, TR= 2400 ms, TI=
1,000 ms, flip angle= 8◦ (Mugler III & Brookeman, 1990), one at each of the 4 scanning
sessions. The structural images for each subject were inspected visually, images of lower
quality were rejected, and the remaining 1-4 MP-RAGE images for each subject were
mutually registered and averaged using a validated method (Black et al., 2001).
Image preprocessing
BOLD images from each subject were preprocessed to reduce artifacts, including
correction for intensity differences due to interleaved acquisition, interpolation for slice
time correction, correction for head movement, and alignment to atlas space (Hershey et
al., 2004). Image intensity was adjusted on a frame-by-frame basis so that each frame had
a whole-brain modal value of 1,000 (Ojemann et al., 1997). Frames were smoothed using
a 6 mm (FWHM) Gaussian filter and resampled to (3 mm)3 cubic voxels. To minimize
motion-related artifact, frames were removed if framewise displacement exceeded 0.9 mm
(Siegel et al., 2014).
The 63 frames of the ASL run were smoothed using a 5.7 mm (FWHM) Gaussian filter
(resolution chosen to best match the final smoothing estimated from the BOLD images)
and rigidly aligned using a method validated in humans and other species (Black et al.,
2001; Black et al., 2014). Cerebral blood flow (CBF) was computed in each voxel for each
tag-control EPI pair as described (Wang et al., 2003b). The aligned EPI images were also
summed to facilitate later alignment steps, and the summed, aligned EPI images from each
run were mutually aligned within each subject and summed across runs. The resulting
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Figure 2 ASL blood flow image of one subject’s 2-back run before levodopa on the placebo day.
summed EPI images from each subject were affine registered to a target image in Talairach
and Tournoux space made using validated methods from these subjects’ structural MR
images (Hershey et al., 2004). The products of the registration matrix from this step and
the matrices from the within-run mutual registration step were used to resample the 31
tag–control pair CBF images from each run into atlas space images with (3 mm)3 cubic
voxels in a single resampling step. As with the BOLD, to minimize motion-related artifact
we removed tag–control pairs if framewise displacement in either EPI image exceeded
0.9 mm (Siegel et al., 2014). One subject’s data was excluded from further analysis because
over half of his frame pairs were removed due to head motion, leaving 12 subjects for all
analyses below. The CBF images in atlas space from the remaining pairs were averaged to
create one atlas-registered CBF image for each ASL run. Each CBF image was scaled to a




The analyses were designed so that each ASL–BOLD comparison included the same
scan sessions from the same group of subjects, and as nearly as possible the same image
smoothness. Furthermore, the images used to compare the modalities were t images from
the same sample, and hence were commensurate. Statistical images were created for each
imaging modality to examine the 2-back task effect, the interaction of the 2-back task with
tozadenant, and the direct comparison of tozadenant versus placebo.
Statistical images
To identify regions of activation and deactivation, we used a mixed-effects approach with
partitioned variance (Penny & Henson, 2007). First, for each study subject, we used a
voxelwise general linear model (GLM) that included main effects of task (2-back vs.
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Table 1 Comparison of BOLD and ASL images.
BOLD ASL
Total acquisition time per scanning session 8.7 min 10.9 min
Acquisition time per session, limited to frames
retained after motion censoring (mean± SD)
8.5± 0.1 min 9.2± 1.1 min
FWHM (x× y× z)a 10.1× 10.5× 9.0 mm 9.4× 10.5× 11 mm
Notes.
a Average of the FWHM estimates across SPM analyses.
fixation), levodopa (during vs. before infusion) and drug (tozadenant vs. placebo), and
their interactions. For each effect analyzed (2-back task, drug-task interaction, drug effect),
SPM12b software (www.fil.ion.ucl.ac.uk/spm/) generated a contrast image for each subject
from ASL data, and fIDL (http://www.nil.wustl.edu/∼fidl/) did the same for BOLD images
(also correcting for linear drift within each run). Note for each subject, every contrast
image for ASL data was derived from the same set of scans, and similarly for the BOLD
data. These single-subject contrast images (t images) were used as input to second-level
statistical parametric mapping (SPM) analyses based on a voxelwise GLM with a covariate
for subject age and a factor for sex. At each voxel, GLM contrasts generated t images to
test whether the single-subject contrast images at that voxel were significantly less than or
greater than zero, across subjects, taking age and sex into account. After thresholding at
the t value corresponding to uncorrected p = .001, multiple comparisons correction was
performed with the cluster false discovery rate set at p = .05. Approximate anatomical
locations of peaks in the statistical images were provided by the Talairach Daemon client
(www.talairach.org) (Lancaster et al., 1997; Lancaster et al., 2000).
Secondary analysis: effects of levodopa
The study design was optimized for tozadenant rather than levodopa, and the levodopa
dose was relatively low, so analyses examining the effect of levodopa were secondary.
To investigate the effects of levodopa we created statistical images of the levodopa effect
(comparing scans acquired during the levodopa infusion to scans prior to infusion), of the
interaction of the 2-back task with levodopa, and of the 3-way interaction of the 2-back
task, levodopa and tozadenant.
RESULTS
Cross-modality image comparison
The final resolution of the (3 mm)3 ASL and BOLD images was similar (Table 1). Total ac-
quisition time was about 25% longer for ASL than BOLD, but acquisition time for the data
actually submitted to statistical analysis was much more similar (Table 1), largely because
each head movement lost 5.2 s of data in the ASL data versus 2.0 s in the BOLD data.
Task activation
The working memory task serves as a positive control, and significant regional activations
were identified. The analysis using the ASL data identified one significant activation cluster
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1 515 13.9 <.001 12.29 −40 3 33 Left precentral gyrus (BA 6)
2 471 12.7 <.001 9.80 4 12 48 Right superior frontal gyrus (BA 6)
3 327 8.8 <.001 10.75 56−54−12 Right inferior temporal gyrus (BA20)
4 224 6.0 <.001 9.40 −40 − 63−24 Cerebellum, left posterior lobe
5 223 6.0 <.001 8.73 44 27 30 Right middle frontal gyrus (BA9)
6 166 4.5 <.001 7.53 −10−18 12 Left caudate
7 163 4.4 <.001 6.38 44−48 51 Right postcentral gyrus (BA2)
8 142 3.8 <.001 13.42 32 21 6 Right insula (BA 13)
9 127 3.4 <.001 12.94 −28 21 3 Left claustrum
10 108 2.9 <.001 8.41 −2 − 81−27 Left cerebellum
11 47 1.3 <.001 7.69 −28−57 42 Left superior parietal lobule (BA7)
12 22 0.6 .016 6.30 −38 48 18 Left superior frontal gyrus (BA10)
Notes.
a BA, Brodmann area.
(22 voxels= 0.6 ml, corrected p = 0.030, peak t = 5.88 at−32,−3, 57, left middle frontal
gyrus, Brodmann area [BA] 6) (Fig. S1). The analysis using the BOLD data identified 12
significant clusters; the largest cluster also included−32,−3, 57 (515 voxels= 13.9 ml),
corrected p < .001, peak t = 12.29 at−40, 3, 33 (left precentral gyrus, BA6) (see Table 2,
Fig. S2A). There were no significant deactivations in the ASL data, while the analysis using
the BOLD data identified 11 significant deactivation clusters (the largest had volume 2,142
voxels= 57.8 ml, corrected p< .001, peak t= 12.70 at−4,−54, 12, left posterior cingulate,
BA29) (Table 3, Fig. S2B).
Drug effect
The task-drug interaction (tozadenant×2-back) showed no significant results for ASL or
BOLD (Figs. S3 and S4). However, the drug vs. placebo contrast from the same ASL data
revealed significant rCBF decreases on tozadenant in the thalamus bilaterally (Table 4,
Fig. 3, Fig. S5). There were no significant clusters of increased rCBF. As expected, the same
contrast with the BOLD data found no significant clusters of activation or deactivation
(Fig. S6). Table 5 summarizes all these contrasts.
Levodopa effect
There were no significant clusters for the pure levodopa effect (Figs. S7 and S8), the task-
levodopa interaction (Figs. S9 and S10), or the 3-way interaction (Figs. S11 and S12) in
either the ASL or the BOLD images.
DISCUSSION
Cognitive-pharmacological interaction is a common phMRI approach. However, in this
study neither ASL nor BOLD analyses detected significant clusters for the interaction
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p (FDR) Peak t Atlas location of
peak t value
Anatomical locationa
1 2,142 57.8 <.001 12.70 −4−54 12 Left posterior cingulate (BA29)
2 507 13.7 <.001 8.03 4 12 0 Right caudate
3 360 9.7 <.001 7.76 −38−18 21 Left insula (BA13)
4 132 3.6 <.001 8.78 −44−75 30 Left angular gyrus (BA39)
5 104 2.8 <.001 6.72 52−75 21 Right middle temporal gyrus (BA19)
6 65 1.8 <.001 6.81 −56 0−15 Left middle temporal gyrus (BA21)
7 59 1.6 <.001 7.57 26 6−21 Right uncus (BA28)
8 46 1.2 .001 9.74 10−51−42 Right cerebellar tonsil
9 42 1.1 .001 6.50 32−72−33 Right cerebellum, pyramis
10 40 1.1 .001 6.68 −34−18 0 Left lentiform nucleus
11 29 0.8 .006 7.18 14 39 54 Right superior frontal gyrus (BA8)
Notes.
a BA, Brodmann area.
Table 4 Significant clusters of decreased rCBF on tozadenant.
# Cluster volume,
voxels (cm3)
p (FDR) Peak t Atlas location Anatomical location of peak t
1 25 (0.68) .004 5.67 8,−15, 9 Right medial dorsal nucleus of thalamus
2 10 (0.27) .049 5.17 −8,−21, 9 Left medial dorsal nucleus of thalamus
Table 5 Summary of activation clusters for all contrasts.
Contrast Number of significant clusters
ASL BOLD
2-back activation 1 12
2-back deactivation 0 11
Tozadenant× 2-back activation 0 0
Tozadenant× 2-back deactivation 0 0
Tozadenant activation 0 0
Tozadenant deactivation 2 0
of tozadenant with 2-back task activation, whereas directly comparing rCBF on versus
off drug using ASL did reveal significant differences. The drug-induced rCBF decreases
detected by ASL are in the thalamus, consistent with animal studies suggesting that
adenosine A2a receptor antagonists inhibit neuronal activity in the indirect pathway,
including in pallidal afferents to thalamus (Black et al., 2010b).
Although the sample size was modest, positive controls built into the experiment
confirm that the absence of significant drug effects in the BOLD analysis cannot
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Figure 3 Coronal (A), axial (B) and sagittal (C) sections showing the significant CBF decreases on
tozadenant 60 mg twice daily. Colored voxels indicate p< .001 uncorrected; the corrected p value is .004
for the cluster in right thalamus and .049 for the left thalamus (see also Table 4).
comfortably be attributed to inadequate image quality or limited data: these same scans
were quite adequate to detect significant cognitive (2-back task) effects in a pattern
consistent with previous functional imaging studies on working memory (Barch et al.,
2012; Bledowski, Kaiser & Rahm, 2010). BOLD is generally more sensitive than ASL for
comparisons like this one that can be made over very brief time intervals (a minute or so)
(Wang et al., 2003a). However, noise in BOLD data worsens as the time between activation
and control acquisitions increases (Aguirre et al., 2002; Ollinger, Corbetta & Shulman, 2001;
Zarahn, Aguirre & D’Esposito, 1997), and this temporal instability likely explains why the
BOLD data could not detect direct drug effects between sessions. By contrast, the temporal
stability of ASL may suit it better to measure the effects of medications, which after all
often have been optimized to require only a few doses a day, and hence have slow onset
and wearing off of action (Aguirre et al., 2002; Wang et al., 2011; Zelaya et al., in press). A
different solution to BOLD’s limited temporal stability is functional connectivity fMRI
with and without drug (Schwarz et al., 2007).
Comparing scans from different sequences was feasible here because both BOLD and
ASL data were acquired during the same scan sessions in the same subjects, and because
the images submitted to statistical analysis were of similar spatial smoothness. Also, in each
scan session, the ASL scans immediately followed the two BOLD runs, so that any slowly
evolving effects of practice, fatigue or drug should be similar for the two modalities.
Limitations of this study include the imperfect matching between ASL and BOLD
of total acquisition time and original voxel size. The different original voxel size is in
part a technical limitation because ASL is best suited to acquiring read-out planes in
inferior-to-superior order, whereas BOLD can be acquired with even and odd read-out
planes interleaved. We used an early version of this pASL sequence, and newer ASL
sequences may be even more sensitive to pharmacological agents (Alsop et al., in press).
Additionally, most of the subjects in this sample are male, consistent with the higher
prevalence of Parkinson disease in men. However, sex differences likely are irrelevant to the
comparison of BOLD and ASL.
These were the first Parkinson disease patients ever to receive the drug, so ideal dosing
was not yet known. In fact, the initial imaging results from this study suggested that
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higher doses might be more effective (Black et al., 2010b). Thus the later phase 2b study
included higher doses of tozadenant, and demonstrated significant reductions in mean
daily “off” time at 120 or 180 mg twice daily but not at 60 mg twice daily (Hauser et al.,
2014). Thus another limitation of the present study is that more robust phMRI results may
have been found with a higher dose of drug. Nevertheless, tozadenant at 60 mg twice daily
did improve tapping speed compared to placebo, whether on or off levodopa (Black et al.,
2010a). More importantly, early studies with a new compound most appropriately begin
with low doses, and the drug challenge ASL approach was able to detect alterations in brain
activity even at these relatively low doses.
One additional advantage of this study comes from the following consideration. A
drug that produces symptomatic effects, for instance a feeling of alertness, may cause
secondary effects on neuronal activity via the effect on emotional state in addition to any
direct neuronal effects (including the neuronal effects that themselves produce the sense
of alertness). The same reasoning applies to any placebo effect that may be heightened if
the subject notices any drug effect. In this study, most subjects were unable to distinguish
whether they were taking the active drug or the placebo, allowing more straightforward
interpretation of the drug’s effects on neuronal activity.
Decreased thalamic rCBF with tozadenant was also the most significant result of the
previously published analysis of ASL data from this study (Black et al., 2010b). The present
analysis detected fewer significant voxels, but several factors account for the difference. In
order to match the BOLD data, the present analysis excluded half the ASL data (acquired
during additional behavior states for which there were no comparable BOLD data) and
smoothed the data less than in the published analysis. The current analysis also excluded
subjects with excessive movement or poor 2-back task performance, censored frames for
head motion, and improved the correction for global CBF.
Despite the small size and low dose, ASL was sensitive enough to capture phMRI
activity. While BOLD may be able to capture task-drug interaction or direct pharma-
cological effects with larger sample sizes or higher doses, early pharmacological studies
are more feasible in smaller samples using lower doses. In summary, these data offer
direct, head-to-head evidence using a cognitive task that phMRI using ASL and pure
pharmacologic activation may be more sensitive than task-drug-interaction BOLD
phMRI, especially for early stage phMRI studies.
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